Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the 340b Contract Pharmacies topic
No spam. Unsubscribe anytime.
Debate erupts over 340B contract‑pharmacy restrictions and a clearinghouse alternative
Summary
Sponsors and safety‑net providers told the committee that manufacturer restrictions on contract pharmacies have reduced pharmacy access and 340B benefits for clinics and patients; manufacturers and trade groups warned the state should not limit audit or claims‑flagging tools used to detect duplicate discounts.
The House Committee on Behavioral Health and Health Care held extended testimony on legislation that would limit manufacturers’ ability to restrict which contract pharmacies covered 340B entities may use and would authorize a clearinghouse approach for verifying 340B claims rather than relying on a claims modifier.
Lede/nut: Sponsors described two complementary policy strands: HB 2,057 (technical change to authorize a neutral clearinghouse for transactional validation in commercial claims) and HB 2,385 (ban on manufacturer contract restrictions that narrow the pharmacies covered entities can designate). Supporters — FQHCs, hospital systems and pharmacy advocates — said pharmacy restrictions implemented in 2020 have forced clinics either to lose discounts or force patients to travel to limited pharmacies; they asked the Legislature to restore long‑standing practice that let covered entities contract with multiple pharmacies to serve patients across large geographies.
Opposition and transparency concerns: Pharma industry representatives and the Biotechnology Innovation Organization opposed statutory limits on manufacturer auditing and other transparency protections. They argued the state should not restrict manufacturers’ ability to require transactional claims flags (a claims modifier) because those flags help detect duplicate discounts and diversion; federal audits by HRSA and OIG have, they said, revealed program misuse in other states.
Clearinghouse proposal: Supporters described a neutral clearinghouse model (Oregon’s Medicaid exclusion/clearinghouse was described as a reference example) in which pharmacies’ dispensed claims and covered entity prescription lists are adjudicated by a trusted third party; that third party would provide validated datasets to manufacturers and PBMs without requiring the pharmacy to resubmit claims (current practice can require claims resubmission days later). Supporters said the clearinghouse reduces administrative burden for contract pharmacies — some national chains have resisted providing claim modifiers — and provides the accurate, consolidated data that manufacturers request.
Economic and policy stakes: Opponents warned the 340B program has grown dramatically and must be reined in or reformed at the federal level; they argued state statutes that prevent transaction‑level flags risk duplicate discounts and reduce program oversight. Supporters argued the clearinghouse is the “gold standard” and already used in Medicaid in Oregon. Testimony included both technical details and examples of how local clinics use 340B savings to subsidize uncompensated care, medication assistance programs and rural pharmacy access.
Committee action: The hearing included testimony from a wide array of stakeholders; no committee vote was held. Lawmakers directed stakeholders to continue working on technical language.
